首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection
【24h】

Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection

机译:根治性手术切除后可切除的胰管腺癌患者术前早期复发的危险因素

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Postoperative early recurrence (ER) in patients with pancreatic ductal adenocarcinoma (PDAC) is frequently encountered after curative intent surgery. Nonetheless, clinical significance and risk factors of ER after surgery for PDAC have not been extensively investigated. The aim of this study was to determine preoperative risk predictors for ER in patients with PDAC after upfront surgery. Methods: Eighty-one consecutive patients with PDAC who underwent curative intent surgical resection at Kangbuk Samsung Hospital between January 2004 and May 2015 were enrolled. ER was defined as tumor relapse within 6 months after surgery. Results: ER occurred in 26 patients (32.1%), whereas 49 patients (60.5%) had late recurrence (≥ 6 months after surgery), and 6 patients had no recurrence (7.4%). Univariate analysis showed that C-reactive pro-tein (CRP) > 3.0 mg/dL, modified Glasgow prognostic score (mGPS) = 2, decrease of total lymphocyte count by > 50% of baseline value in the preoperative period, prognostic nutritional index (PNI) < 45, neutrophil-to-lymphocyte ratio (NLR) ≥ 3, and preoperative maximum standardized uptake value (SUVmax) were sig-nificantly associated with ER. Multivariate logistic regression analysis revealed that CRP > 3.0 mg/dL, de-crease of total lymphocyte count by > 50% of baseline value, and preoperative SUVmax were significant and independent contributors of ER in patients with resectable PDAC who underwent curative intent surgery. Conclusions: Postoperative ER for resectable PDAC was frequent with poor prognosis after curative intent upfront surgery. It is reasonable to suggest that there is a subgroup of resectable PDAC patients at high-risk of ER and neoadjuvant therapy should be considered in these patients in a clinical trial setting.
机译:背景:根治性手术后,胰腺导管腺癌(PDAC)患者经常发生术后早期复发(ER)。尽管如此,PDAC术后ER的临床意义和危险因素尚未得到广泛研究。这项研究的目的是确定前期手术后PDAC患者ER的术前危险因素。方法:纳入2004年1月至2015年5月间在江北三星医院接受根治性手术切除的81例PDAC患者。 ER被定义为手术后6个月内肿瘤复发。结果:ER发生26例(占32.1%),而49例(占60.5%)有晚期复发(术后≥6个月),有6例无复发(7.4%)。单因素分析表明,C反应蛋白(CRP)> 3.0 mg / dL,改良的格拉斯哥预后评分(mGPS)= 2,术前总淋巴细胞计数降低基线值的50%以上,预后营养指数( PNI)<45,中性粒细胞与淋巴细胞之比(NLR)≥3,术前最大标准化摄取值(SUVmax)与ER显着相关。多元logistic回归分析显示,可切除的PDAC患者接受根治性手术后,CRP> 3.0 mg / dL,总淋巴细胞计数减少>基线值的50%,以及术前SUVmax均是ER的重要独立原因。结论:根治性意图前期手术后可切除PDAC的ER频繁发生,预后较差。合理地建议,有一组可切除的PDAC患者处于ER高危状态,在临床试验中应考虑对这些患者进行新辅助治疗。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2018年第005期|450-455|共6页
  • 作者

    Nam Hee Kim; Hong Joo Kim;

  • 作者单位

    Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea;

    Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 04:27:24
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号